Table 3.
Baseline characteristics for all 35 patients with liver metastases from ocular melanoma
| Parameter | N | Percentage |
|---|---|---|
| Gender | ||
| Men | 16 | 46 |
| Women | 19 | 54 |
| Age, yr [median (range)] | 59 (41–71) | … |
| BMI, kg/m2 [median (range)] | 25 (20–32) | … |
| Tumor location | ||
| Choroid | 19 | 54 |
| Choroid with ciliary corpus involvement | 12 | 34 |
| Ciliary corpus | 4 | 11 |
| Type of metastases | ||
| Synchronous | 4 | 11 |
| Metachronous | 31 | 89 |
| Mutations in liver metastases | ||
| GNAQ | 21 | 60 |
| GNA11 | 12 | 34 |
| No GNAQ/GNA11 | 2 | 6 |
| Time between diagnosis primary tumor and liver metastases, months [median (range)] | 28 (0–71) | … |
| Prior therapy for liver metastases | ||
| Systemic therapya | 8 | 23 |
| Regional therapyb | 4 | 11 |
| Regional and systemic therapy | 2 | 6 |
| None | 21 | 60 |
| Radiological aspect metastases | ||
| Hypovascular | 3 | 9 |
| Hypervascular | 26 | 74 |
| Mixed | 6 | 17 |
| Total number of metastases ≥ 10 | 20 | 57 |
| Diameter of largest metastasis ≥ 3 cm | 14 | 40 |
| LDH level, IU/L [median (range)] | 196 (78–657) | … |
| Elevated LDH levelc | 8 | 23 |
| Elevated AFP leveld | 7 | 20 |
AFP alkaline phosphatase, BMI body mass index, GNAQ guanine nucleotide-binding protein G(q) subunit alpha, GNA11 guanine nucleotide-binding protein G(Y) subunit alpha-11, LDH lactate dehydrogenase, SD standard deviation, ULN upper limit of normal
aTreatment in randomized phase II SUMIT-trial (selumetinib with dacarbazine vs. placebo) or phase I AEB071-study (protein kinase C inhibitor), ipilimumab, or dendritic cell therapy
bRadiofrequency ablation and/or metastasectomy
cNormal limits 0–247 for men and women
dNormal limits 0–115 U/L for men and 0–98 U/L for women